litlas
Log inCreate account

Marc Peeters

Active 1985–2025

208
Papers
35,263
Citations
99
h-index
201
i10-index

Citations

Citations per year for Marc Peeters1987: 2 citations1990: 4 citations1991: 9 citations1992: 6 citations1993: 3 citations1994: 5 citations1995: 13 citations1996: 18 citations1997: 19 citations1998: 24 citations1999: 45 citations2000: 63 citations2001: 84 citations2002: 113 citations2003: 115 citations2004: 137 citations2005: 129 citations2006: 142 citations2007: 144 citations2008: 187 citations2009: 311 citations2010: 311 citations2011: 294 citations2012: 264 citations2013: 283 citations2014: 337 citations2015: 305 citations2016: 265 citations2017: 276 citations2018: 233 citations2019: 854 citations2020: 829 citations2021: 851 citations2022: 703 citations2023: 537 citations2024: 973 citations2025: 461 citations2026: 16 citations1988–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,631 citing papers, 21% of this breakdownChina: 1,069 citing papers, 8.5% of this breakdownItaly: 923 citing papers, 7.4% of this breakdownUnited Kingdom: 802 citing papers, 6.4% of this breakdownGermany: 776 citing papers, 6.2% of this breakdownFrance: 623 citing papers, 5% of this breakdownBelgium: 512 citing papers, 4.1% of this breakdownSpain: 512 citing papers, 4.1% of this breakdownNetherlands: 479 citing papers, 3.8% of this breakdownJapan: 403 citing papers, 3.2% of this breakdownCanada: 396 citing papers, 3.1% of this breakdownAustralia: 340 citing papers, 2.7% of this breakdown
0%21%Other 24.5%

Institutions

Fields

  • Medicine56.8%
  • Biochemistry, Genetics and Molecular Biology26.7%
  • Immunology and Microbiology6.1%
  • Engineering4.7%
  • Neuroscience0.7%
  • Nursing0.6%
  • Other4.4%

Topics

  • Colorectal Cancer Treatments and Studies7.4%
  • Inflammatory Bowel Disease3.7%
  • Cancer Genomics and Diagnostics3.6%
  • Genetic factors in colorectal cancer2.4%
  • Lung Cancer Treatments and Mutations2.3%
  • Colorectal Cancer Surgical Treatments2.1%
  • Other78.5%

Coauthors

All papers

Open in search
  1. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Authors: Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio García‐Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Éveline Boucher, Marc Peeters, Ben Tran, Heinz‐Josef Lenz, Alberto Zaniboni, Howard S. Höchster, James M. Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu - New England Journal of Medicine 2015 cited by 1,431

  2. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

    Authors: John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, Elena Élez, David L. Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios Bekaii‐Saab, Eric Van Cutsem, Marc Peeters, Marc Van den Evnde, Thierry André, Christophe Borg, Matthieu Sarabi, François Ghiringhelli, Benoist Chibaudel, Salvatore Siena, Chiara Cremolini, Maria Giulia Zampino, Elena Élez, Susana R. Keranen, Ramón Salazar, Pilar Alfonso, John H. Strickler, Andrea Cercek, Kimmie Ng, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, David L. Bajor, Tanios Bekaii‐Saab, Olumide B. Gbolahan, Patrick M. Boland, Daniel Berg, Federico Sanchez, Timothy F. Goggins, Federico Sanchez, Howard A. Burris, Johanna C. Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel V.T. Catenacci, Jun Gong, Ignacio Garrido‐Laguna, Gene Grant Finley, Benjamin A. Weinberg, Anthony F. Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher S. Chen, James M. Ford, Madappa N. Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer H. Shao, Scott McKenney, Spencer H. Shao - The Lancet Oncology 2023 cited by 245

  3. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

    Authors: Dirk Arnold, B. Lueza, Jean-Yves Douillard, Marc Peeters, Heinz‐Josef Lenz, Alan P. Venook, Volker Heinemann, Eric Van Cutsem, Jean‐Pierre Pignon, Josep Tabernero, Andrés Cervantes, Fortunato Ciardiello - Annals of Oncology 2017 cited by 836

  4. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.

    Authors: Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Maria Di Bartolomeo, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry André, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, Cristina Grávalos Castro, John H. Strickler, Daniel Barrios, Qi Yan, Takahiro Kamio, Kojiro Kobayashi, Takayuki Yoshino - Journal of Clinical Oncology 2023 cited by 77

  5. Cellular senescence in cancer: clinical detection and prognostic implications

    Authors: Andreas Domen, Christophe Deben, Jasper Verswyvel, Tal Flieswasser, Hans Prenen, Marc Peeters, Filip Lardon, An Wouters - Journal of Experimental & Clinical Cancer Research 2022 cited by 91

  6. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

    Authors: Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David Chang - Journal of Clinical Oncology 2008 cited by 3,152

  7. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

    Authors: Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Filippo Pietrantonio, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry André, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, Cristina Grávalos Castro, Hung‐Chih Hsu, John H. Strickler, Tae‐You Kim, Yongjun Cha, Daniel Barrios, Qi Yan, Takahiro Kamio, Kojiro Kobayashi, Aislyn Boran, Makito Koga, John Allard, Takayuki Yoshino - The Lancet Oncology 2024 cited by 126

  8. Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives

    Authors: Joe Ibrahim, Marc Peeters, Guy Van Camp, Ken Op de Beeck - European Journal of Cancer 2022 cited by 103

  9. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Authors: Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean–Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado - Journal of Clinical Oncology 2007 cited by 1,998

  10. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy

    Authors: Jorrit De Waele, Tias Verhezen, Sanne van der Heijden, Zwi Berneman, Marc Peeters, Filip Lardon, An Wouters, Evelien Smits - Journal of Experimental & Clinical Cancer Research 2021 cited by 109

  11. Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review

    Authors: Ruben Van den Brande, Erwin M. J. Cornips, Marc Peeters, Piet Ost, Charlotte Billiet, Erik Van de Kelft - Journal of bone oncology 2022 cited by 190

  12. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Authors: Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao - The Lancet 2011 cited by 1,052

  13. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

    Authors: Timothy Price, Marc Peeters, Tae Won Kim, Jin Li, Stefano Cascinu, Paul Ruff, Atilli Satya Suresh, Anne Thomas, Sergei Tjulandin, Kathy Zhang, Swaminathan Murugappan, Roger Sidhu - The Lancet Oncology 2014 cited by 470

  14. Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects

    Authors: Jinthe Van Loenhout, Marc Peeters, Annemie Bogaerts, Evelien Smits, Christophe Deben - Antioxidants 2020 cited by 97

  15. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

    Authors: Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Jorrit De Waele, Christophe Hermans, Hilde Lambrechts, Bart Cuypers, Kris Laukens, Esther Bartholomeus, Vasiliki Siozopoulou, Winnok H. De Vos, Marc Peeters, Evelien Smits, Christophe Deben - Redox Biology 2021 cited by 109

  16. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma

    Authors: Jinthe Van Loenhout, Laurie Freire Boullosa, Delphine Quatannens, Jorrit De Waele, Céline Merlin, Hilde Lambrechts, Ho Wa Lau, Christophe Hermans, Abraham Lin, Filip Lardon, Marc Peeters, Annemie Bogaerts, Evelien Smits, Christophe Deben - Cells 2021 cited by 72

  17. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

    Authors: Antoine Hollebecque, Hyun C. Chung, Maria J. de Miguel, Antoine Italiano, Jean-Pascal Machiels, Chia-Chi Lin, Neesha C. Dhani, Marc Peeters, Victor Moreno, Wu-Chou Su, Kay Hoong Chow, Violeta R. Galvao, Michelle Carlsen, Danni Yu, Anna M. Szpurka, Yumin Zhao, Shelly L. Schmidt, Leena Gandhi, Xiaojian Xu, Yung-Jue Bang - Clinical Cancer Research 2021 cited by 62

  18. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

    Authors: Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannová, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua K. Sabari, Sonya C. Chapman, Wei Zhang, Boris Calderón, Daniel A. Peterson - Investigational New Drugs 2021 cited by 58

  19. Probiotics enhance the clearance of human papillomavirus-related cervical lesions

    Authors: Véronique Verhoeven, Nathalie Renard, Amin Makar, Paul Van Royen, John-Paul Bogers, Filip Lardon, Marc Peeters, Marc Baay - European Journal of Cancer Prevention 2012 cited by 133

  20. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells

    Authors: Jinthe Van Loenhout, Tal Flieswasser, Laurie Freire Boullosa, Jorrit De Waele, Jonas R.M. Van Audenaerde, Elly Marcq, Julie Jacobs, Abraham Lin, Eva Lion, Heleen Dewitte, Marc Peeters, Sylvia Dewilde, Filip Lardon, Annemie Bogaerts, Christophe Deben, Evelien Smits - Cancers 2019 cited by 113

  21. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors

    Authors: Antoine Hollebecque, Hyun Cheol Chung, de Miguel, Maria J., Antoîne Italiano, Jean‐Pascal Machiels, Chia‐Chi Lin, Neesha C. Dhani, Marc Peeters, Víctor Moreno, Wu‐Chou Su, Kay Hoong Chow, Violeta Régnier Galvão, Michelle Carlsen, Danni Yu, Anna M. Szpurka, Yumin Zhao, Shelly Schmidt, Leena Gandhi, Xiaojian Xu, Yung‐Jue Bang - 2021 cited by 43

  22. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

    Authors: Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka, Jean‐Luc Van Laethem, Lara Lipton, Hanno Riess, Cezary Szczylik, Malcolm J. Moore, Marc Peeters, G. Bodoky, Masafumi Ikeda, Bohuslav Melichar, Radim Němeček, S. Ohkawa, Anna Świeboda-Sadlej, Sergei Tjulandin, Eric Van Cutsem, Robert D. Loberg, Vincent Haddad, Jennifer Gansert, Bruce Allen Bach, Alfredo Carrato - Annals of Oncology 2015 cited by 164

  23. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer

    Authors: Maxim Le Compte, Edgar Cardenas De La Hoz, Sofía Peeters, Felicia Rodrigues Fortes, Christophe Hermans, Andreas Domen, Evelien Smits, Filip Lardon, Timon Vandamme, Abraham Lin, Steve Vanlanduit, Geert Roeyen, Steven Van Laere, Hans Prenen, Marc Peeters, Christophe Deben - npj Precision Oncology 2023 cited by 37

  24. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

    Authors: P. Rutgeerts, Marc Peeters, Martin Hiele, G. Vantrappen, F Pennincx, Raymond Aerts, Raymond Kerremans, K Goboes - The Lancet 1991 cited by 760